[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-336292-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-336292-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","an-on-treatment-decreased-trend-of-serum-il-6-and-il-8-as-predictive-markers-quickly-reflects-short-term-efficacy-of-pd-1-blockade-immunochemotherapy-in-patients-with-advanced-gastric-cancer","An On-Treatment Decreased Trend of Serum IL-6 and IL-8 as Predictive Markers Quickly Reflects Short-Term Efficacy of PD-1 Blockade Immunochemotherapy in Patients with Advanced Gastric Cancer","","Immunotherapy shows benefit in advanced gastric cancer, but response is limited to a subset, creating a need for rapid, reliable prognostic indicators. This retrospective study compared 36 patients receiving combined anti-PD-1 immunochemotherapy with 20 patients receiving chemotherapy alone, measuring serum TNF-α, IL-1β, IL-2R, IL-6, IL-8, IL-10, and IL-17 at three time points. Patients on immunochemotherapy exhibited a general cytokine rise after treatment initiation, while responders showed sustained decreases in IL-6 or IL-8. The marker combination IL-6, IL-8, and CEA provided optimal short-term predictive performance, supporting accessible blood biomarkers for early treatment guidance.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/an-on-treatment-decreased-trend-of-serum-il-6-and-il-8-as-predictive-markers-quickly-reflects-short-term-efficacy-of-pd-1-blockade-immunochemotherapy-in-patients-with-advanced-gastric-cancer/336292/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/an-on-treatment-decreased-trend-of-serum-il-6-and-il-8-as-predictive-markers-quickly-reflects-short-term-efficacy-of-pd-1-blockade-immunochemotherapy-in-patients-with-advanced-gastric-cancer/336292.png","ImageObject",300,407,{"name":42,"@type":43},"Eliana","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are IL-6 and IL-8 investigated as predictive markers in advanced gastric cancer?","Question",{"text":63,"@type":64},"Because advanced gastric cancer does not respond uniformly to PD-1 inhibitor immunotherapy, the study aims to find cytokine-based indicators that quickly reflect short-term treatment efficacy and help improve patient selection.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the study designed to evaluate predictive performance?",{"text":68,"@type":64},"It retrospectively compared 36 advanced gastric cancer patients receiving combined anti-PD-1 immunochemotherapy with 20 patients receiving chemotherapy alone, measuring serum cytokines at three distinct time intervals.",{"name":70,"@type":61,"acceptedAnswer":71},"What cytokine trends distinguish treatment responders from non-responders?",{"text":72,"@type":64},"While immunochemotherapy was associated with an overall rise in cytokines after initiation, patients who benefited showed decreased IL-6 and/or IL-8 levels throughout treatment, unlike those who did not benefit.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},336292,1790147584,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":115,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","Hindawi  \nJournal of Immunology Research Volume 2024, Article ID 3604935, 9 pages [https://doi.org/10.1155/2024/3604935](https://doi.org/10.1155/2024/3604935)  \nResearch Article  \nAn On-Treatment Decreased Trend of Serum IL-6 and IL-8 as Predictive Markers Quickly Reﬂects Short-Term Efﬁcacy of PD-1 Blockade Immunochemotherapy in Patients with Advanced Gastric Cancer  \nJiameng Liu, 1 Yufei Mao ,2 Chaoming Mao , 1 Deqiang Wang ,3 Liyang Dong , 1 and Wei Zhu 4  \n1Department of Nuclear Medicine, The Afﬁliated Hospital of Jiangsu University, Zhenjiang, Jiangsu 212001, China.  \n2Department of Ultrasound Medicine, The Afﬁliated Hospital of Jiangsu University, Zhenjiang, Jiangsu 212001, China.  \n3Department of Oncology, Institute of Digestive Diseases, The Afﬁliated Hospital of Jiangsu University, Zhenjiang,  \nJiangsu 212001, China  \n4School of Medicine, Jiangsu University, Zhenjiang, Jiangsu 212013, China  \nCorrespondence should be addressed to Yufei Mao; [1000012984@ujs.edu.cn](1000012984@ujs.edu.cn)  \nReceived 19 October 2023; Revised 19 April 2024; Accepted 3 May 2024; Published 14 May 2024  \nAcademic Editor: Arif Siddiqui  \nCopyright © 2024 Jiameng Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.  \nObjective. Immunotherapy has proven effective in treating advanced gastric cancer (AGC), yet its beneﬁts are limited to a subset of patients. Our aim is to swiftly identify prognostic biomarkers using cytokines to improve the precision of clinical guidance and decision-making for PD-1 inhibitor-based cancer immunotherapy in AGC. Materials and Methods. The retrospective study compared 36 patients with AGC who received combined anti-PD-1 immunotherapy and chemotherapy (immunochemotherapy) with a control group of 20 patients who received chemotherapy alone. The concentrations ofTNF-α, IL-1β, IL-2R, IL-6, IL-8, IL-10, and IL-17 in the serum were assessed using chemiluminescence immunoassay at three distinct time intervals following the commencement of immunochemotherapy. Results. When compared to controls, patients undergoing immunochemotherapy demonstrated a generalized rise in cytokine levels after the start of treatment. However, patients who beneﬁted from immunochemotherapy showed a decrease in IL-6 or IL-8 concentrations throughout treatment (with varied trends observed for IL-1β, IL-2R, IL-10, IL-17, and TNF-α) was evident in patients beneﬁting from immunochemotherapy but not in those who did not beneﬁt. Among these markers, the combination of IL-6, IL-8, and CEA showed optimal predictive performance for short-term efﬁcacy of immunochemotherapy in AGC patients. Conclusion. Reductions in IL-6/IL-8 levels observed during immunochemotherapy correlated with increased responsiveness to treatment effectiveness. These easily accessible blood-based biomarkers are predictive and rapid and may play a crucial role in identifying individuals likely to derive beneﬁts from PD-1 blockade immunotherapy.  \n1. Introduction  \nTumor immunotherapy represents a cutting-edge therapeutic avenue following conventional treatments like surgery, radiotherapy, and chemotherapy, showing promise in clinical applications [1] . However, its effectiveness varies widely among patients, posing a challenge in predicting responses. Through its interaction with programmed cell death ligand 1 (PD-L1), programmed cell death protein-1 (PD-1) functions as an immune system suppressor, preventing effector T cells from  \ntargeting cancer cells and promoting the growth of tumors [2] . PD-L1 expression in tumor tissue stands as the sole established biomarker for predicting immunotherapy response [3] . PD-1 blockade, a novel immunotherapy strategy, has gained widespread usage in treating diverse cancers, with several PD-1inhibitor drugs approved by the Food and Drug Administration (FDA) for advanced gastric ","cbCaikj1Gqa0j2in","https://ap.wps.com/l/cbCaikj1Gqa0j2in","pdf",334682,"English","# Introduction\n## Rationale for biomarker-based response prediction\n# Materials and Methods\n## Study design and patient groups\n## Cytokine measurement timeline\n# Results\n## Cytokine dynamics after treatment start\n## Biomarker performance for short-term efficacy\n# Conclusion","[{\"question\":\"Why are IL-6 and IL-8 investigated as predictive markers in advanced gastric cancer?\",\"answer\":\"Because advanced gastric cancer does not respond uniformly to PD-1 inhibitor immunotherapy, the study aims to find cytokine-based indicators that quickly reflect short-term treatment efficacy and help improve patient selection.\"},{\"question\":\"How was the study designed to evaluate predictive performance?\",\"answer\":\"It retrospectively compared 36 advanced gastric cancer patients receiving combined anti-PD-1 immunochemotherapy with 20 patients receiving chemotherapy alone, measuring serum cytokines at three distinct time intervals.\"},{\"question\":\"What cytokine trends distinguish treatment responders from non-responders?\",\"answer\":\"While immunochemotherapy was associated with an overall rise in cytokines after initiation, patients who benefited showed decreased IL-6 and/or IL-8 levels throughout treatment, unlike those who did not benefit.\"}]","An On-Treatment Decreased Trend of Serum IL-6 and IL-8 as Predictive Markers Quickly Reflects Short-Term Efficacy of PD-1 Blockade Immunochemotherapy in Patients with Advanced Gastric Cancer | PDF",1790014428,23,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/01f1dcc474a491fa466b004c9849aef6.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dc039a440788a1ffaded4fed8328020a.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cabd4d49f84b27e85a67efcf2de1767b.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/88b086d9866e16a1c2f480080716589a.webp",980,1306]